id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-013486-hg87xsyr	Buttery, Philip C.	Gene and Cell-Based Therapies for Parkinson’s Disease: Where Are We?	2020-10-30		.txt	text/plain	16105	637	45	As such, these recombinant GF protein therapies are probably best considered as preparing the ground both for the more tractable genetic approach of GF GTs. Despite earlier work using LV-mediated GDNF delivery in animal models, the first GF to come to the clinic in the format of a GT was actually NRTN rather than GDNF, and used an AAV2 vector, rather than LVs. AAV2-NRTN was manufactured by the Californian biotech company Ceregene, with their product CERE-120 providing neuronal expression of NRTN as a pure protein without viral coding sequences [111] . This sort of regulation would require additional gene regulatory sequences and might be difficult to achieve within the restrictive payload of AAVs. This issue might drive a move to use LVs for GF therapy in due course, as these vectors can facilitate regulatable expression in different cells systems including the delivery of GFs to the striatum [131] . Phase 1 trial of convection-enhanced delivery of adeno-associated virus encoding glial cell line-derived neurotrophic factor in patients with advanced Parkinson's disease	./cache/cord-013486-hg87xsyr.txt	./txt/cord-013486-hg87xsyr.txt